ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Bellen Chemistry Further Validates its R&D Facilities by Participating in VERIF.i®, Scientist.com’s Supplier Pre-assessment Program

Chinese CRO/CDMO specializing in chemical synthesis and chemistry, manufacturing and controls (CMC) services successfully completes manufacturing site inspection

Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i®, the company’s supplier pre-assessment program, has been used to conduct an onsite assessment of Bellen Chemistry’s facility in Shandong, China, which opened in 2017. Scientist.com developed VERIF.i to help its marketplace service providers showcase capabilities to their customers while improving quality standards internally.

Bellen Chemistry is a leading contract research organization (CRO)/contract development and manufacturing organization (CDMO) committed to providing chemical synthesis for small molecule compounds in new drug development, from initial lead compound screening and optimization to preclinical and clinical studies. Bellen has created a one-stop-shop chemistry and chemical manufacturing service platform ranging from compound selection to final API GMP manufacturing.

“With more than 1,000 R&D projects and over 3,000 innovative new molecules being completed each year at our facilities, Bellen places the utmost importance on the quality of our operational processes and the dedicated frontline staff carrying them out,” stated Bob Liu, PhD, Co-founder & CEO of Bellen Chemistry. “By showcasing our compliance with international standard management processes and strict oversight of production processes, VERIF.i allows us to demonstrate our commitment to quality across the biopharma industry in North America, Europe and Japan.”

VERIF.i provides suppliers of regulated research services, including human biospecimen acquisition, animal welfare and chemistry, manufacturing, and controls (CMC), the platform to proactively communicate their standards against established criteria developed specifically for the biopharma industry through onsite pre-assessments. The pre-assessments are conducted by independent, third-party auditors to maintain the integrity of the site visit. Pre-assessments help suppliers such as Bellen Chemistry demonstrate their quality and capabilities, while also helping pharma and biotech customers purchase regulated services in an accelerated manner with more confidence and less risk.

“When sourcing regulated services that inherently have high reputational risk, resource-intensive onsite pre-assessments of partner laboratories become an essential part of the due diligence process,” stated Matt McLoughlin, SVP of Categories and Compliance at Scientist.com. “By creating a standardized process set against pre-defined criteria, VERIF.i addresses this barrier for both customers and suppliers, saving time and money. The program also enables suppliers like Bellen to differentiate themselves from their peers by sharing independent insight into their facilities, personnel and processes.”

VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/.

About Bellen Chemistry

Bellen Chemistry has been providing chemistry CRO/CDMO services as an integrated Contract Chemistry Service Organization since 2010. With years of accumulated technical advantages and experience in chemical synthesis of small molecule compounds, Bellen has built a one-stop-shop chemistry service platform, supporting big pharmas, biotech innovators and new drug development institutions for their research programs from discovery to commercial stage through comprehensive chemistry solutions.

Our R&D, production, sales and operation team are based globally and at present, Bellen has nearly 1,000 employees worldwide, of which our technical team accounts for around 50%.

About Scientist.com

Scientist.com is a privately held, San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace for complex custom experiments that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments.

Visit scientist.com to learn more.

Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.